Table 3 Treatment-related adverse events since the initiation of radiotherapy

From: Neoadjuvant chemoradiotherapy plus sintilimab in proficient mismatch repair locally advanced rectal cancer with intermediate/high-immunoscore (SILAR): a single-arm phase II trial

Treatment-related AEs

Patients (n = 46)

Any grade

Grade 3

Any AE, n (%)

35 (76.1)

7 (15.2)

Leukopenia

32 (69.6)

3 (6.52)

Nausea

30 (65.2)

0

Radiation proctitis

25 (54.3)

0

Fatigue

25 (54.3)

0

Anal pain

20 (43.5)

1 (2.17)

Neutropenia

20 (43.5)

2 (4.35)

Thrombocytopenia

18 (39.1)

0

Peripheral neurotoxicity

18 (39.1)

0

Vomiting

12 (26.1)

0

Anorexia

12 (26.1)

0

Fever

12 (26.1)

0

Anemia

11 (23.9)

0

ALT increased

11 (23.9)

0

AST increased

10 (21.7)

0

Archorrhagia

6 (13.0)

0

Constipation

3 (6.52)

0

Abdominal pain

2 (4.35)

0

Immune-related AEs, n (%)

2 (4.35)

1 (2.17)

Diarrhea

1 (2.17)

0

Drug rash

1 (2.17)

1 (2.17)

  1. AE adverse event, ALT alanine transaminase, AST aspartate transaminase.
Back to article page